放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展

魏莉; 罗荣城

魏莉 , 罗荣城

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 3: (153-157)

引用本文:

Citation:

放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展

魏莉,
罗荣城

510515 广州, 南方医科大学南方医院肿瘤中心
中图分类号: R817.5

Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas

Center of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
CLC number: R817.5

摘要: 放射免疫治疗(radioimmunotherapy,RIT)属于内照射治疗,可以用较少的单克隆抗体耦联放射性核素,在肿瘤局部产生足够的电离辐射生物学效应,达到高效低毒的治疗效果。B细胞淋巴瘤有较高的复发比例,其CD20抗原表达率达90%以上,且不易从细胞膜上脱落,因此¹³¹I-利妥昔单抗CD20是B细胞淋巴瘤放免治疗的最佳靶点。目前已有数个放免治疗的药物,如:¹³¹I-托西莫单抗(¹³¹I-tositumomab)、¹³¹I-Rituximab、⁹⁰Y-替坦异贝莫单抗(⁹⁰Y-ibritumomabtiuxetan)等,用于B细胞淋巴瘤的临床治疗,它们具有各自的优缺点。使用结果表明:肿瘤部位的高吸收剂量保证了治疗的有效性,其对非靶器官的照射剂量是安全的。最主要的副反应包括:血小板减少症、中性粒细胞减少症、胃肠道反应及甲状腺功能减低症。在取得满意结果的同时,B细胞淋巴瘤放免治疗仍存在许多问题,人们正致力于更进一步的研究解决此类问题,以取得更好的治疗效果。
- 放射免疫疗法 /
- 淋巴瘤,B细胞 /
- 抗原,CD20 /
- 抗体,抗独特型 /
- 放射性同位素
Abstract: Radioimmunotherapy(RIT), a kind of internal radiation therapy, can achieve high performance and low toxicity by fewer monoclonal antibodys couple radioactive nuclides, created sufficient ionization biologic effect on tumor. B cell lymphomas has higher relapsed rate, CD20 is the best target of RIT on B cell lymphomas because the expression rate of it on B cell lymphomas is above 90%, and it is not desquamated easily. There are severy drug of RIT, such as ¹³¹I-tositumomab, ¹³¹I-Rituximab, and ⁹⁰Y-ibritumomab tiuxetan. Each one has its advantages and disadvantages. Clinical trials indicates they are effective on B cell lymphomas, and safe to non-targetted organs. The main side effects include thrombopenia, neutropenia, gastrointestinal tract response, and hypothyroidism. While satisfied results have attained, many problems are existed. All researchers do their best to resolve there problems for better therapy results.
- Radioimmunotherapy /
- Lymphomas,B cell /
- Antigens,CD20 /
- Antibodies,anti-idiotypic /
- Radioisotope
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies.J Lab Clin Med, 1999, 134(5):445-450.
[2]	Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies. Oncologist, 2000, 5(5):376-384.
[3]	Press OW, Eary JF, Cooley T, et al. A phase Ⅰ/Ⅱ trial of iodine-131-tositumomab(anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 2000, 96(9):2934-2942.
[4]	Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol, 2005, 23(3):461-467.
[5]	Kaminski MS, Tuck M, Estes J, et al. ¹³¹I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 2005, 352(5):441-449.
[6]	Seldin DW. Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma. Nucl Med Technol, 2002, 30(3):109-114.
[7]	Nair M, Mark R, Anderson P, et al. Bexxar Protocol CP98-020:Preliminary results with ¹³¹I-labeled antibody in patients with non-Hodgkin's lymphoma refractory to chemotherapy and rituxan.Orlando, FL:ASCO, 2005. 612.
[8]	Gregory A J, Leonard PJ, Vose M, et al. Superior outcomes associated with earlier use:Experience with tositumomab and iodine ¹³¹I-tositumomab in 1177 patients with low-grade, follicular,and transformed non-Hodgkin's lymphoma (NHL). Orlando, FL:ASCO, 2005. 575.
[9]	Turner JH, Martindale AA, Boucek J, et al. ¹³¹I-Anti CD20 radioimmunotherapy of relapsed or refraclory non-Hodgkin's lymphoma:a phase Ⅱ clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm, 2003, 18(4):513-524.
[10]	张军一, 罗海涛, 李爱民, 等.¹³¹I-美罗华治疗难治性复发性B细胞淋巴瘤9例.解放军医学杂志,2003,28(2):190.
[11]	Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 2002, 20(15):3262-3269.
[12]	Joyce J, Schuster MW, McCook B, et al. Experience with yttrium-90 ibritumomab tiuxetan (Zevalin) after autologous stem cell transplant(ASCT) in patients with non-Hodgkin's lymphoma (NHL). Orlando,FL:ASCO, 2005. 602.
[13]	Shipley DL, Greco FA, Spigel DR, et al. Rituximab with short duration chemotherapy followed by ⁹⁰Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma:Update of a Minnie Pearl Cancer Research Network phase Ⅱ trial. Orlando,FL:ASCO, 2005. 579.
[14]	Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade,follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol,2003, 21(7):1263-1270.

[1]	蔡秋琼 , 杜明华 . ¹³¹Ⅰ-rituximab治疗B细胞非霍奇金淋巴瘤. 国际放射医学核医学杂志, 2008, 32(2): 72-74.
[2]	于晓明 , 樊飞跃 . 肿瘤放射免疫疗法研究进展. 国际放射医学核医学杂志, 2006, 30(2): 80-83.
[3]	蒋宁一 , 熊玥 . 放射免疫导向治疗真菌感染灶的研究. 国际放射医学核医学杂志, 2008, 32(3): 137-139.
[4]	张凯秀 , 王雪梅 , 赵建民 . 放射性核素显像探针在细胞凋亡中的研究进展. 国际放射医学核医学杂志, 2018, 42(6): 559-564, 576. doi: 10.3760/cma.j.issn.1673-4114.2018.06.015
[5]	赵亮 , 林勤 , 吴华 , 陈皓鋆 . 放射性核素标记的成纤维细胞活化蛋白抑制剂在肿瘤诊疗一体化中的研究进展. 国际放射医学核医学杂志, 2022, 46(10): 629-634. doi: 10.3760/cma.j.cn121381-202112017-00226
[6]	冯春玲 . 放射免疫治疗中载体的研究进展. 国际放射医学核医学杂志, 2007, 31(2): 77-79.
[7]	郭艾楠 , 魏玲格 , 傅鹏 . ¹³¹I-肿瘤细胞核人鼠嵌合单克隆抗体治疗实体瘤的研究进展. 国际放射医学核医学杂志, 2013, 37(2): 120-123. doi: 10.3760/cma.j.issn.1673-4114.2013.02.015
[8]	姚红霞 , 张金山 . 微波消融和¹³¹I-肿瘤细胞核人鼠嵌合单克隆抗体联合治疗肺癌. 国际放射医学核医学杂志, 2012, 36(5): 264-268, 306. doi: 10.3760/cma.j.issn.1673-4114.2012.05.002
[9]	张富海 , 孟召伟 , 谭建 . 肺癌的放射性核素分子靶向治疗. 国际放射医学核医学杂志, 2012, 36(3): 145-147. doi: 10.3760/cma.j.issn.1673-4114.2012.03.005
[10]	朱虹静 , 董爱生 , 左长京 . 放射性核素显像在肾肿瘤诊断中的应用. 国际放射医学核医学杂志, 2021, 45(1): 41-46. doi: 10.3760/cma.j.cn121381-202004035-00008

点击查看大图

计量

文章访问数: 1167
HTML全文浏览量: 103
PDF下载量: 3

放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展

魏莉
罗荣城

510515 广州, 南方医科大学南方医院肿瘤中心

收稿日期: 2005-08-30

关键词:

摘要: 放射免疫治疗(radioimmunotherapy,RIT)属于内照射治疗,可以用较少的单克隆抗体耦联放射性核素,在肿瘤局部产生足够的电离辐射生物学效应,达到高效低毒的治疗效果。B细胞淋巴瘤有较高的复发比例,其CD20抗原表达率达90%以上,且不易从细胞膜上脱落,因此¹³¹I-利妥昔单抗CD20是B细胞淋巴瘤放免治疗的最佳靶点。目前已有数个放免治疗的药物,如:¹³¹I-托西莫单抗(¹³¹I-tositumomab)、¹³¹I-Rituximab、⁹⁰Y-替坦异贝莫单抗(⁹⁰Y-ibritumomabtiuxetan)等,用于B细胞淋巴瘤的临床治疗,它们具有各自的优缺点。使用结果表明:肿瘤部位的高吸收剂量保证了治疗的有效性,其对非靶器官的照射剂量是安全的。最主要的副反应包括:血小板减少症、中性粒细胞减少症、胃肠道反应及甲状腺功能减低症。在取得满意结果的同时,B细胞淋巴瘤放免治疗仍存在许多问题,人们正致力于更进一步的研究解决此类问题,以取得更好的治疗效果。